Pfizer today released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11. The data, culled from a phase 2/3 trial, indicates that two, 10-microgram doses of Pfizer’s mRNA vaccine, administered 21 days apart, resulted in a strong immune response against SARS-CoV-2. Pfizer said the data would be included in a “near-term” application to the Food and Drug Administration for emergency use authorization in the 5-11 age group. The drug maker also indicated that it would soon have sufficient trial data for children under 5 for submission to FDA.

Related News Articles

Headline
A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
The Food and Drug Administration today authorized a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at…
Headline
The federal government will purchase 10 million treatment courses of the COVID-19 oral antiviral Paxlovid from Pfizer if the Food and Drug Administration…
Headline
The Occupational Safety and Health Administration has suspended activities related to implementation and enforcement of its Emergency Temporary Standard on…
Headline
The Occupational Safety and Health Administration has suspended activities related to implementation and enforcement of its Emergency Temporary Standard on…